Video Insights
Video Insights
Advertisement
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
View More
Richard Newcomb, MDTransplantation & Cellular Therapy | February 26, 2024
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
Shambavi Richard, MDTransplantation & Cellular Therapy | February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
Pieter Sonneveld, MD, PhDMyeloma | February 16, 2024
The addition of daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy improved PFS.
Justin Taylor, MDChronic Lymphocytic Leukemia | February 14, 2024
The study defined mutations that develop resistance to BTK inhibitors and evaluated the BTK degrader NX-2127 in CLL.
Shambavi Richard, MDVideo Insights | February 8, 2024
The scales are shifting in the STEM fields as more women step into positions of responsibility, leadership, and influence.
Advertisement
Mariia Mikhaleva, MDVideo Insights | February 2, 2024
Mariia Mikhaleva MD, a research fellow at the Dana-Farber Cancer Institute, describes how it felt to receive the award.
Mariia Mikhaleva, MDChronic Lymphocytic Leukemia | January 26, 2024
The presence of two or more mutations are associated with high-risk cell features.
Chadi Nabhan, MD, MBA, FACPTransplantation & Cellular Therapy | January 26, 2024
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Paula Rodríguez Otero, MDMyeloma | February 15, 2024
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Dwight Macero, PA-C, MSMyeloma | January 8, 2024
Physician Assistant Dwight Macero, one of the clinical consultants on the survey, offers his thoughts on the results.
Leyla Shune, MDMyeloma | January 5, 2024
Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting.
Ajai Chari, MDTransplantation & Cellular Therapy | January 24, 2024
The investigation is "likely not going to change the risk-benefit profile of these approved products," Dr. Chari said.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Rafael Fonseca, MDMyeloma | January 4, 2024
Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment.
Hana Safah, MDVideo Insights | January 24, 2024
The panel shares their outlook for the future of MDS research and treatment.
Hana Safah, MDVideo Insights | December 19, 2023
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
Hana Safah, MDVideo Insights | December 19, 2023
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
Hana Safah, MDVideo Insights | December 19, 2023
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
Advertisement
Advertisement
Editorial Board